Advances in oncological treatments have significantly improved patient survival rates. However, these therapies often introduce the risk of cancer therapy-related cardiac dysfunction (CTRCD), necessitating robust monitoring strategies. The newly released CTRCD echocardiography guidance (2026 focused update) provides a comprehensive framework for clinicians to evaluate and manage cardiac health in cancer patients. This update reflects recent developments in cardio-oncology and emphasizes the importance of multidisciplinary collaboration between cardiologists and oncologists.

Core Parameters: LVEF and Global Longitudinal Strain

The guidance reinforces the role of left ventricular ejection fraction (LVEF) as a primary parameter for monitoring cardiotoxicity. However, it also highlights that global longitudinal strain (GLS) is a more sensitive marker for detecting subclinical myocardial injury. Clinicians should use GLS to identify early changes before a significant drop in LVEF occurs. Additionally, the document stresses the need for measurement accuracy and quality control to ensure reliable longitudinal tracking of a patient's cardiac function.

Standardized Protocols and Monitoring Timelines

Following the CTRCD echocardiography guidance involves a structured approach throughout the treatment continuum. Baseline evaluations are mandatory before starting potentially cardiotoxic therapies, such as anthracyclines or HER2-targeted agents. During treatment, surveillance typically occurs every three months, though intervals may vary based on individual risk profiles. Furthermore, the 2026 update introduces specific recommendations for long-term surveillance following radiotherapy and highlights the unique cardiovascular complications associated with immune checkpoint inhibitors, particularly myocarditis.

Integrating Advanced Imaging and AI

Modern clinical practice increasingly benefits from three-dimensional (3D) echocardiography and artificial intelligence (AI). The 2026 update advocates for 3D LVEF assessment whenever possible, as it offers superior accuracy compared to 2D methods. Moreover, AI-driven automation is helping to standardize measurements and reduce inter-observer variability. Consequently, these technological advancements facilitate the early detection of cardiotoxicity, allowing for timely intervention and the optimization of cancer therapy management.

Frequently Asked Questions

What is the primary goal of the 2026 CTRCD echocardiography update?

The update aims to provide evidence-based recommendations for the early detection and monitoring of cardiotoxicity, ensuring that cancer patients receive optimal cardiovascular care without unnecessary interruptions to their life-saving treatments.

Why is Global Longitudinal Strain (GLS) emphasized over LVEF alone?

GLS is more sensitive to subtle myocardial changes. It can detect subclinical cardiac dysfunction often before LVEF shows a significant decline, enabling earlier initiation of cardioprotective therapies.

How does the guidance address immune checkpoint inhibitors (ICIs)?

The guidance specifically addresses the risk of ICI-related myocarditis, providing protocols for prompt echocardiographic evaluation when cardiac symptoms or elevated biomarkers are detected in patients on immunotherapy.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Tanaka H et al. Practical guidance for echocardiography for cancer therapy-related cardiac dysfunction: 2026 focused update. J Echocardiogr. 2026 May 03. doi: 10.1007/s12574-026-00731-4. PMID: 42070216.

2. Lyon AR et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229-4361.

3. Dobson R et al. BSE and BCOS Guideline for Transthoracic Echocardiographic Assessment of Adult Cancer Patients Receiving Anthracyclines and/or Trastuzumab. JACC CardioOncol. 2021;3(1):1-16.